Metabolic Surgery: Weight Loss, Diabetes, and Beyond

Journal of the American College of Cardiology

Volumn 71, Issue 6, 2018, Pages 670-687

  Pareek, Manan ^a,b   Schauer, Philip R ^c   Kaplan, Lee M ^d   Leiter, Lawrence A ^e   Rubino, Francesco ^f   Bhatt, Deepak L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c LERNER RESEARCH INSTITUTE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

bariatric; cardiovascular risk; diabetes; metabolic; obesity

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; AMFEBUTAMONE PLUS NALTREXONE; AMYLIN DERIVATIVE; INCRETIN; INSULIN; LIRAGLUTIDE; LORCASERIN; MEGLITINIDE; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHENTERMINE PLUS TOPIRAMATE; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE; TETRAHYDROLIPSTATIN;

BARIATRIC SURGERY; BILIOPANCREATIC BYPASS; BODY WEIGHT LOSS; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; GASTRIC BANDING; GASTROINTESTINAL SURGERY; GLYCEMIC CONTROL; HUMAN; INSULIN RELEASE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; METABOLIC SURGERY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; ROUX-EN-Y GASTRIC BYPASS; SLEEVE GASTRECTOMY; ENERGY METABOLISM; GLUCOSE BLOOD LEVEL; INSULIN RESISTANCE; METABOLISM; PHYSIOLOGY; PROCEDURES; TRENDS;

BARIATRIC SURGERY; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; HUMANS; INSULIN RESISTANCE; OBESITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; WEIGHT LOSS;

EID: 85044860956     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2017.12.014     Document Type: Review

References (128)

1. NCD Risk Factor Collaboration (NCD-RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. Lancet 387 (2016), 1377–1396.
2. GBD 2015 Obesity Collaborators, Afshin, A., Forouzanfar, M.H., et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med 377 (2017), 13–27.
3. Ogden, C.L., Carroll, M.D., Kit, B.K., Flegal, K.M., Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 311 (2014), 806–814.
4. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet 387 (2016), 1513–1530.
5. International Diabetes Federation. Diabetes Atlas, 8th edition. 2017. Available at: www.diabetesatlas.org/. Accessed December 22, 2017.
6. Poirier, P., Giles, T.D., Bray, G.A., et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association scientific statement on obesity and heart disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 113 (2006), 898–918.
7. Tuah, N.A., Amiel, C., Qureshi, S., Car, J., Kaur, B., Majeed, A., Transtheoretical model for dietary and physical exercise modification in weight loss management for overweight and obese adults. Cochrane Database Syst Rev(10), 2011, CD008066.
8. Dombrowski, S.U., Knittle, K., Avenell, A., Araujo-Soares, V., Sniehotta, F.F., Long term maintenance of weight loss with non-surgical interventions in obese adults: systematic review and meta-analyses of randomised controlled trials. BMJ, 348, 2014, g2646.
9. Look AHEAD Research Group. Eight-year weight losses with an intensive lifestyle intervention: the Look AHEAD study. Obesity (Silver Spring) 22 (2014), 5–13.
10. Diabetes Prevention Program Research Group, Knowler, W.C., Fowler, S.E., et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program outcomes study. Lancet 374 (2009), 1677–1686.
11. Lindstrom, J., Peltonen, M., Eriksson, J.G., et al. Improved lifestyle and decreased diabetes risk over 13 years: long-term follow-up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia 56 (2013), 284–293.
12. Jensen, M.D., Ryan, D.H., Apovian, C.M., et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol 63 (2014), 2985–3023.
13. Garvey, W.T., Mechanick, J.I., Brett, E.M., et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract 22:Suppl 3 (2016), 1–203.
14. Apovian, C.M., Aronne, L.J., Bessesen, D.H., et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 100 (2015), 342–362.
15. European Medicines Agency. The European Medicines Agency recommends Suspension of the Marketing Authorisation of Acomplia. 2008. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2009/11/news_detail_000244.jsp&mid=WC0b01ac058004d5c1. Accessed December 22, 2017.
16. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA Recommends Against the Continued Use of Meridia (Sibutramine). 2010. Available at: https://www.fda.gov/Drugs/DrugSafety/ucm228746.htm. Accessed December 22, 2017.
17. American Diabetes Association. Obesity management for the treatment of type 2 diabetes. Diabetes Care 40:Suppl 1 (2017), S57–S63.
18. Khera, R., Murad, M.H., Chandar, A.K., et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA 315 (2016), 2424–2434.
19. Marso, S.P., Daniels, G.H., Brown-Frandsen, K., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
20. American Diabetes Association. Pharmacologic approaches to glycemic treatment. Diabetes Care 40:Suppl 1 (2017), S64–S74.
21. Gloy, V.L., Briel, M., Bhatt, D.L., et al. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ, 347, 2013, f5934.
22. Angrisani, L., Santonicola, A., Iovino, P., et al. Bariatric surgery and endoluminal procedures: IFSO worldwide survey 2014. Obes Surg 27 (2017), 2279–2289.
23. American Society for Metabolic and Bariatric Surgery. Estimate of Bariatric Surgery Numbers, 2011-2015. 2016. Available at: https://asmbs.org/resources/estimate-of-bariatric-surgery-numbers. Accessed December 22, 2017.
24. Poirier, P., Cornier, M.A., Mazzone, T., et al. Bariatric surgery and cardiovascular risk factors: a scientific statement from the American Heart Association. Circulation 123 (2011), 1683–1701.
25. Heneghan, H.M., Nissen, S., Schauer, P.R., Gastrointestinal surgery for obesity and diabetes: weight loss and control of hyperglycemia. Curr Atheroscler Rep 14 (2012), 579–587.
26. le Roux, C.W., Aylwin, S.J., Batterham, R.L., et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 243 (2006), 108–114.
27. Miras, A.D., le Roux, C.W., Mechanisms underlying weight loss after bariatric surgery. Nat Rev Gastroenterol Hepatol 10 (2013), 575–584.
28. Khorgami, Z., Shoar, S., Andalib, A., Aminian, A., Brethauer, S.A., Schauer, P.R., Trends in utilization of bariatric surgery, 2010-2014: sleeve gastrectomy dominates. Surg Obes Relat Dis 13 (2017), 774–778.
29. Hanipah, Z.N., Schauer, P.R., Surgical treatment of obesity and diabetes. Gastrointest Endosc Clin N Am 27 (2017), 191–211.
30. Madsbad, S., Dirksen, C., Holst, J.J., Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery. Lancet Diabetes Endocrinol 2 (2014), 152–164.
31. Arble, D.M., Sandoval, D.A., Seeley, R.J., Mechanisms underlying weight loss and metabolic improvements in rodent models of bariatric surgery. Diabetologia 58 (2015), 211–220.
32. Mahawar, K.K., Sharples, A.J., Contribution of malabsorption to weight loss after Roux-en-Y gastric bypass: a systematic review. Obes Surg 27 (2017), 2194–2206.
33. Aarts, E.O., Dogan, K., Koehestanie, P., Aufenacker, T.J., Janssen, I.M., Berends, F.J., Long-term results after laparoscopic adjustable gastric banding: a mean fourteen year follow-up study. Surg Obes Relat Dis 10 (2014), 633–640.
34. Marceau, P., Hould, F.S., Simard, S., et al. Biliopancreatic diversion with duodenal switch. World J Surg 22 (1998), 947–954.
35. Ionut, V., Burch, M., Youdim, A., Bergman, R.N., Gastrointestinal hormones and bariatric surgery-induced weight loss. Obesity (Silver Spring) 21 (2013), 1093–1103.
36. Buchwald, H., Avidor, Y., Braunwald, E., et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 292 (2004), 1724–1737.
37. Chang, S.H., Stoll, C.R., Song, J., Varela, J.E., Eagon, C.J., Colditz, G.A., The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. JAMA Surg 149 (2014), 275–287.
38. Yu, J., Zhou, X., Li, L., et al. The long-term effects of bariatric surgery for type 2 diabetes: systematic review and meta-analysis of randomized and non-randomized evidence. Obes Surg 25 (2015), 143–158.
39. Hutter, M.M., Schirmer, B.D., Jones, D.B., et al. First report from the American College of Surgeons Bariatric Surgery Center Network: laparoscopic sleeve gastrectomy has morbidity and effectiveness positioned between the band and the bypass. Ann Surg 254 (2011), 410–420 discussion 420–2.
40. Dixon, J.B., O'Brien, P.E., Playfair, J., et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 299 (2008), 316–323.
41. Schauer, P.R., Kashyap, S.R., Wolski, K., et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 366 (2012), 1567–1576.
42. Mingrone, G., Panunzi, S., De Gaetano, A., et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 366 (2012), 1577–1585.
43. Ikramuddin, S., Korner, J., Lee, W.J., et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA 309 (2013), 2240–2249.
44. Liang, Z., Wu, Q., Chen, B., Yu, P., Zhao, H., Ouyang, X., Effect of laparoscopic Roux-en-Y gastric bypass surgery on type 2 diabetes mellitus with hypertension: a randomized controlled trial. Diabetes Res Clin Pract 101 (2013), 50–56.
45. Wentworth, J.M., Playfair, J., Laurie, C., et al. Multidisciplinary diabetes care with and without bariatric surgery in overweight people: a randomised controlled trial. Lancet Diabetes Endocrinol 2 (2014), 545–552.
46. Courcoulas, A.P., Goodpaster, B.H., Eagleton, J.K., et al. Surgical vs medical treatments for type 2 diabetes mellitus: a randomized clinical trial. JAMA Surg 149 (2014), 707–715.
47. Halperin, F., Ding, S.A., Simonson, D.C., et al. Roux-en-Y gastric bypass surgery or lifestyle with intensive medical management in patients with type 2 diabetes: feasibility and 1-year results of a randomized clinical trial. JAMA Surg 149 (2014), 716–726.
48. Parikh, M., Chung, M., Sheth, S., et al. Randomized pilot trial of bariatric surgery versus intensive medical weight management on diabetes remission in type 2 diabetic patients who do NOT meet NIH criteria for surgery and the role of soluble RAGE as a novel biomarker of success. Ann Surg 260 (2014), 617–622 discussion 622–4.
49. Ding, S.A., Simonson, D.C., Wewalka, M., et al. Adjustable gastric band surgery or medical management in patients with type 2 diabetes: a randomized clinical trial. J Clin Endocrinol Metab 100 (2015), 2546–2556.
50. Cummings, D.E., Arterburn, D.E., Westbrook, E.O., et al. Gastric bypass surgery vs intensive lifestyle and medical intervention for type 2 diabetes: the CROSSROADS randomised controlled trial. Diabetologia 59 (2016), 945–953.
51. Puzziferri, N., Roshek, T.B. 3rd, Mayo, H.G., Gallagher, R., Belle, S.H., Livingston, E.H., Long-term follow-up after bariatric surgery: a systematic review. JAMA 312 (2014), 934–942.
52. Sjöström, L., Lindroos, A.K., Peltonen, M., et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 351 (2004), 2683–2693.
53. Sjöström, L., Peltonen, M., Jacobson, P., et al. Bariatric surgery and long-term cardiovascular events. JAMA 307 (2012), 56–65.
54. Sjöström, L., Review of the key results from the Swedish Obese Subjects (SOS) trial: a prospective controlled intervention study of bariatric surgery. J Intern Med 273 (2013), 219–234.
55. Maciejewski, M.L., Arterburn, D.E., Van Scoyoc, L., et al. Bariatric surgery and long-term durability of weight loss. JAMA Surg 151 (2016), 1046–1055.
56. Mingrone, G., Panunzi, S., De Gaetano, A., et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet 386 (2015), 964–973.
57. Schauer, P.R., Bhatt, D.L., Kirwan, J.P., et al. Bariatric surgery versus intensive medical therapy for diabetes: 5-year outcomes. N Engl J Med 376 (2017), 641–651.
58. Kashyap, S.R., Bhatt, D.L., Wolski, K., et al. Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment. Diabetes Care 36 (2013), 2175–2182.
59. Rubino, F., Nathan, D.M., Eckel, R.H., et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care 39 (2016), 861–877.
60. Sjöström, L., Peltonen, M., Jacobson, P., et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 311 (2014), 2297–2304.
61. Carlsson, L.M., Peltonen, M., Ahlin, S., et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med 367 (2012), 695–704.
62. Schauer, P.R., Mingrone, G., Ikramuddin, S., Wolfe, B., Clinical outcomes of metabolic surgery: efficacy of glycemic control, weight loss, and remission of diabetes. Diabetes Care 39 (2016), 902–911.
63. Schauer, P.R., Bhatt, D.L., Kirwan, J.P., et al. Bariatric surgery versus intensive medical therapy for diabetes: 3-year outcomes. N Engl J Med 370 (2014), 2002–2013.
64. Kirwan, J.P., Aminian, A., Kashyap, S.R., Burguera, B., Brethauer, S.A., Schauer, P.R., Bariatric surgery in obese patients with type 1 diabetes. Diabetes Care 39 (2016), 941–948.
65. Adams, T.D., Arterburn, D.E., Nathan, D.M., Eckel, R.H., Clinical outcomes of metabolic surgery: microvascular and macrovascular complications. Diabetes Care 39 (2016), 912–923.
66. Rubino, F., Marescaux, J., Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg 239 (2004), 1–11.
67. Drucker, D.J., The role of gut hormones in glucose homeostasis. J Clin Invest 117 (2007), 24–32.
68. Kaplan, L.M., What bariatric surgery can teach us about endoluminal treatment of obesity and metabolic disorders. Gastrointest Endosc Clin N Am 27 (2017), 213–231.
69. Jackness, C., Karmally, W., Febres, G., et al. Very low-calorie diet mimics the early beneficial effect of Roux-en-Y gastric bypass on insulin sensitivity and beta-cell function in type 2 diabetic patients. Diabetes 62 (2013), 3027–3032.
70. Lingvay, I., Guth, E., Islam, A., Livingston, E., Rapid improvement in diabetes after gastric bypass surgery: is it the diet or surgery?. Diabetes Care 36 (2013), 2741–2747.
71. Bojsen-Moller, K.N., Dirksen, C., Jorgensen, N.B., et al. Early enhancements of hepatic and later of peripheral insulin sensitivity combined with increased postprandial insulin secretion contribute to improved glycemic control after Roux-en-Y gastric bypass. Diabetes 63 (2014), 1725–1737.
72. Peterli, R., Steinert, R.E., Woelnerhanssen, B., et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. Obes Surg 22 (2012), 740–748.
73. Dirksen, C., Damgaard, M., Bojsen-Moller, K.N., et al. Fast pouch emptying, delayed small intestinal transit, and exaggerated gut hormone responses after Roux-en-Y gastric bypass. Neurogastroenterol Motil, 25, 2013 346–e255.
74. Rubino, F., Gagner, M., Gentileschi, P., et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 240 (2004), 236–242.
75. Bjorklund, P., Laurenius, A., Een, E., Olbers, T., Lonroth, H., Fandriks, L., Is the Roux limb a determinant for meal size after gastric bypass surgery?. Obes Surg 20 (2010), 1408–1414.
76. Pournaras, D.J., Osborne, A., Hawkins, S.C., et al. Remission of type 2 diabetes after gastric bypass and banding: mechanisms and 2 year outcomes. Ann Surg 252 (2010), 966–971.
77. Vest, A.R., Heneghan, H.M., Schauer, P.R., Young, J.B., Surgical management of obesity and the relationship to cardiovascular disease. Circulation 127 (2013), 945–959.
78. Kopp, H.P., Kopp, C.W., Festa, A., et al. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol 23 (2003), 1042–1047.
79. Shimizu, H., Shimomura, Y., Hayashi, R., et al. Serum leptin concentration is associated with total body fat mass, but not abdominal fat distribution. Int J Obes Relat Metab Disord 21 (1997), 536–541.
80. Trakhtenbroit, M.A., Leichman, J.G., Algahim, M.F., et al. Body weight, insulin resistance, and serum adipokine levels 2 years after 2 types of bariatric surgery. Am J Med 122 (2009), 435–442.
81. Falken, Y., Hellstrom, P.M., Holst, J.J., Naslund, E., Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides. J Clin Endocrinol Metab 96 (2011), 2227–2235.
82. Munzberg, H., Laque, A., Yu, S., Rezai-Zadeh, K., Berthoud, H.R., Appetite and body weight regulation after bariatric surgery. Obes Rev 16:Suppl 1 (2015), 77–90.
83. Auclair, A., Martin, J., Bastien, M., et al. Is there a role for visceral adiposity in inducing type 2 diabetes remission in severely obese patients following biliopancreatic diversion with duodenal switch surgery?. Obes Surg 26 (2016), 1717–1727.
84. Auclair, A., Biertho, L., Marceau, S., et al. Bariatric surgery-induced resolution of hypertension and obstructive sleep apnea: impact of modulation of body fat, ectopic fat, autonomic nervous activity, inflammatory and adipokine profiles. Obes Surg 27 (2017), 3156–3164.
85. Korner, J., Inabnet, W., Febres, G., et al. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. Int J Obes (Lond) 33 (2009), 786–795.
86. Burton, P.R., Brown, W.A., The mechanism of weight loss with laparoscopic adjustable gastric banding: induction of satiety not restriction. Int J Obes (Lond) 35:Suppl 3 (2011), S26–S30.
87. Vest, A.R., Heneghan, H.M., Agarwal, S., Schauer, P.R., Young, J.B., Bariatric surgery and cardiovascular outcomes: a systematic review. Heart 98 (2012), 1763–1777.
88. Zhou, X., Yu, J., Li, L., et al. Effects of bariatric surgery on mortality, cardiovascular events, and cancer outcomes in obese patients: systematic review and meta-analysis. Obes Surg 26 (2016), 2590–2601.
89. Benotti, P.N., Wood, G.C., Carey, D.J., et al. Gastric bypass surgery produces a durable reduction in cardiovascular disease risk factors and reduces the long-term risks of congestive heart failure. J Am Heart Assoc, 6, 2017, e005126.
90. Priester, T., Ault, T.G., Davidson, L., et al. Coronary calcium scores 6 years after bariatric surgery. Obes Surg 25 (2015), 90–96.
91. Vest, A.R., Patel, P., Schauer, P.R., et al. Clinical and echocardiographic outcomes after bariatric surgery in obese patients with left ventricular systolic dysfunction. Circ Heart Fail, 9, 2016, e002260.
92. Sjöström, L., Narbro, K., Sjöström, C.D., et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 357 (2007), 741–752.
93. Jamaly, S., Carlsson, L., Peltonen, M., Jacobson, P., Sjöström, L., Karason, K., Bariatric surgery and the risk of new-onset atrial fibrillation in Swedish obese subjects. J Am Coll Cardiol 68 (2016), 2497–2504.
94. Sundstrom, J., Bruze, G., Ottosson, J., Marcus, C., Naslund, I., Neovius, M., Weight loss and heart failure: a nationwide study of gastric bypass surgery versus intensive lifestyle treatment. Circulation 135 (2017), 1577–1585.
95. Longitudinal Assessment of Bariatric Surgery (LABS) Consortium, Flum, D.R., Belle, S.H., et al. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med 361 (2009), 445–454.
96. Aminian, A., Brethauer, S.A., Kirwan, J.P., Kashyap, S.R., Burguera, B., Schauer, P.R., How safe is metabolic/diabetes surgery?. Diabetes Obes Metab 17 (2015), 198–201.
97. Poulose, B.K., Griffin, M.R., Zhu, Y., et al. National analysis of adverse patient safety for events in bariatric surgery. Am Surg 71 (2005), 406–413.
98. Morino, M., Toppino, M., Forestieri, P., Angrisani, L., Allaix, M.E., Scopinaro, N., Mortality after bariatric surgery: analysis of 13,871 morbidly obese patients from a national registry. Ann Surg 246 (2007), 1002–1007 discussion 1007–9.
99. Fridman, A., Moon, R., Cozacov, Y., et al. Procedure-related morbidity in bariatric surgery: a retrospective short- and mid-term follow-up of a single institution of the American College of Surgeons Bariatric Surgery Centers of Excellence. J Am Coll Surg 217 (2013), 614–620.
100. Sekhar, N., Torquati, A., Youssef, Y., Wright, J.K., Richards, W.O., A comparison of 399 open and 568 laparoscopic gastric bypasses performed during a 4-year period. Surg Endosc 21 (2007), 665–668.
101. Azagury, D., Morton, J.M., Bariatric surgery outcomes in US accredited vs non-accredited centers: a systematic review. J Am Coll Surg 223 (2016), 469–477.
102. Buchwald, H., Estok, R., Fahrbach, K., Banel, D., Sledge, I., Trends in mortality in bariatric surgery: a systematic review and meta-analysis. Surgery 142 (2007), 621–632 discussion 632–5.
103. Khan, S., Rock, K., Baskara, A., Qu, W., Nazzal, M., Ortiz, J., Trends in bariatric surgery from 2008 to 2012. Am J Surg 211 (2016), 1041–1046.
104. Mechanick, J.I., Youdim, A., Jones, D.B., et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient–2013 update: Cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery. Obesity (Silver Spring) 21:Suppl 1 (2013), S1–S27.
105. Parrott, J., Frank, L., Rabena, R., Craggs-Dino, L., Isom, K.A., Greiman, L., American Society for Metabolic and Bariatric Surgery integrated health nutritional guidelines for the surgical weight loss patient 2016 update: micronutrients. Surg Obes Relat Dis 13 (2017), 727–741.
106. 12 deficiency anemia after laparoscopic Roux-en-Y gastric bypass. Obes Surg 18 (2008), 288–293.
107. von Drygalski, A., Andris, D.A., Anemia after bariatric surgery: more than just iron deficiency. Nutr Clin Pract 24 (2009), 217–226.
108. Liu, C., Wu, D., Zhang, J.F., et al. Changes in bone metabolism in morbidly obese patients after bariatric surgery: a meta-analysis. Obes Surg 26 (2016), 91–97.
109. Marsk, R., Jonas, E., Rasmussen, F., Naslund, E., Nationwide cohort study of post-gastric bypass hypoglycaemia including 5,040 patients undergoing surgery for obesity in 1986-2006 in Sweden. Diabetologia 53 (2010), 2307–2311.
110. McLaughlin, T., Peck, M., Holst, J., Deacon, C., Reversible hyperinsulinemic hypoglycemia after gastric bypass: a consequence of altered nutrient delivery. J Clin Endocrinol Metab 95 (2010), 1851–1855.
111. Nguyen, N.T., Magno, C.P., Lane, K.T., Hinojosa, M.W., Lane, J.S., Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the National Health and Nutrition Examination Survey, 1999 to 2004. J Am Coll Surg 207 (2008), 928–934.
112. Aminian, A., Brethauer, S.A., Andalib, A., et al. Individualized metabolic surgery score: procedure selection based on diabetes severity. Ann Surg 266 (2017), 650–657.
113. Sjöström, L., Gummesson, A., Sjöström, C.D., et al. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects study): a prospective, controlled intervention trial. Lancet Oncol 10 (2009), 653–662.
114. Sarkhosh, K., Switzer, N.J., El-Hadi, M., Birch, D.W., Shi, X., Karmali, S., The impact of bariatric surgery on obstructive sleep apnea: a systematic review. Obes Surg 23 (2013), 414–423.
115. Bower, G., Toma, T., Harling, L., et al. Bariatric surgery and non-alcoholic fatty liver disease: a systematic review of liver biochemistry and histology. Obes Surg 25 (2015), 2280–2289.
116. Shah, S.S., Todkar, J.S., Shah, P.S., Cummings, D.E., Diabetes remission and reduced cardiovascular risk after gastric bypass in Asian Indians with body mass index 35 kg/m(2). Surg Obes Relat Dis 6 (2010), 332–338.
117. Panunzi, S., De Gaetano, A., Carnicelli, A., Mingrone, G., Predictors of remission of diabetes mellitus in severely obese individuals undergoing bariatric surgery: do BMI or procedure choice matter? A meta-analysis. Ann Surg 261 (2015), 459–467.
118. 2. Diabetes Care 39 (2016), 924–933.
119. Miras, A.D., le Roux, C.W., Metabolic surgery: shifting the focus from glycaemia and weight to end-organ health. Lancet Diabetes Endocrinol 2 (2014), 141–151.
120. Zhou, X., Li, L., Kwong, J.S., Yu, J., Li, Y., Sun, X., Impact of bariatric surgery on renal functions in patients with type 2 diabetes: systematic review of randomized trials and observational studies. Surg Obes Relat Dis 12 (2016), 1873–1882.
121. Cohen, R.V., Pereira, T.V., Aboud, C.M., et al. Microvascular outcomes after metabolic surgery (MOMS) in patients with type 2 diabetes mellitus and class I obesity: rationale and design for a randomised controlled trial. BMJ Open, 7, 2017, e013574.
122. Schiavon, C.A., Bersch-Ferreira, A.C., Santucci, E.V., et al. Effects of bariatric surgery in obese patients with hypertension: the GATEWAY randomized trial (Gastric Bypass To Treat Obese Patients With Steady Hypertension). Circulation, 2017 Nov 13 [E-pub ahead of print].
123. Adams, S.T., Salhab, M., Hussain, Z.I., Miller, G.V., Leveson, S.H., Obesity-related hypertension and its remission following gastric bypass surgery: a review of the mechanisms and predictive factors. Blood Press 22 (2013), 131–137.
124. Bays, H.E., Jones, P.H., Jacobson, T.A., et al. Lipids and bariatric procedures part 1 of 2: scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: full report. J Clin Lipidol 10 (2016), 33–57.
125. Bays, H., Kothari, S.N., Azagury, D.E., et al. Lipids and bariatric procedures part 2 of 2: scientific statement from the American Society for Metabolic and Bariatric Surgery (ASMBS), the National Lipid Association (NLA), and Obesity Medicine Association (OMA). Surg Obes Relat Dis 12 (2016), 468–495.
126. Inge, T.H., Courcoulas, A.P., Jenkins, T.M., et al. Weight loss and health status 3 years after bariatric surgery in adolescents. N Engl J Med 374 (2016), 113–123.
127. Arterburn, D.E., Bogart, A., Sherwood, N.E., et al. A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg 23 (2013), 93–102.
128. Piche, M.E., Auclair, A., Harvey, J., Marceau, S., Poirier, P., How to choose and use bariatric surgery in 2015. Can J Cardiol 31 (2015), 153–166.